We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

In flu the Swiss

1 September 2005 By Robert Cyran

The Swiss drug group wants to fix its minority investment in the gaffeprone US vaccine maker. Dissatisfaction with Chiron s management has left the group vulnerable to Novartis welltimed bid.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)